Clinical Research Directory
Browse clinical research sites, groups, and studies.
An Extension Study of JR-141 in Patients With Mucopolysaccharidosis Type II
Sponsor: JCR Pharmaceuticals Co., Ltd.
Summary
Multicenter, open-label, single-group, designed to evaluate the long term efficacy and safety of study drug for the treatment of the MPS II.
Key Details
Gender
MALE
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
27
Start Date
2019-09-01
Completion Date
2030-03-31
Last Updated
2025-07-24
Healthy Volunteers
No
Conditions
Interventions
JR-141
IV infusion, 2.0 mg/kg/week
Locations (20)
Fukui Clinical site
Fukui, Japan
Fukuoka Clinical site 2
Fukuoka, Japan
Fukuoka Clinical site
Fukuoka, Japan
Gifu Clinical site
Gifu, Japan
Hiroshima Prefectural Hospital
Hiroshima, Japan
Hokkaido Clinical site
Hokkaido, Japan
Kananagawa Ckinical site
Kanagawa, Japan
Kumamoto Clinical site
Kumamoto, Japan
Okayama Clinical site
Okayama, Japan
Okayama Clinical site 2
Okayama, Japan
Okinawa Clinical site
Okinawa, Japan
Osaka Clinical site 3
Osaka, Japan
Osaka Clinical site 2
Osaka, Japan
Osaka Clinical site
Osaka, Japan
Saitama Clinical site
Saitama, Japan
Shizuoka Clinical site
Shizuoka, Japan
Shizuoka Clinical site 2
Shizuoka, Japan
Tochigi Clinical site
Tochigi, Japan
Tokyo Clinical site
Tokyo, Japan
Tottori Clinical site
Tottori, Japan